Illumina® | Introducing the NovaSeq™ 6000Dx. A new era for the clinical lab.

18 November 2022

The NovaSeq 6000Dx offers immense diagnostic power in an FDA-registered, CE-marked next-generation sequencing platform. From an integrated, unified interface, users can run the NovaSeq 6000Dx instrument in either IVD Mode or Research (RUO) Mode. In IVD Mode, users can access an ever-expanding menu of clinical applications in the fields of oncology, genetic disease, and more. RUO Mode includes all of the standard features available on the NovaSeq 6000 System and supports several methods, including whole-genome sequencing (WGS), whole-exome sequencing (WES), transcriptome profiling, and more. To maximize the potential of the platform, each NovaSeq 6000Dx instrument includes a paired DRAGEN™ Server and license for accurate, ultrarapid secondary data analysis. For large clinical labs, the NovaSeq 6000Dx instrument opens new possibilities across a range of sample types, sequencing methods, and applications. This video explores the NovaSeq 6000 Dx workflow from run planning to analysis. Learn more at For In Vitro Diagnostic Use. Not available in all regions and countries. #illumina #NovaSeq6000Dx #DRAGEN #ClinicalGenomics Subscribe to the Illumina video channel A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos View Illumina webinars View Illumina product videos View Illumina support videos

Share this article on